Free tool
FAERS Monitor: Kloxxado
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212045 or its brand name (Kloxxado, Naloxone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
861
Serious
543
63% of reports
Hospitalization
286
Death reported
102
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue91
- nausea76
- drug ineffective65
- headache58
- pain53
- diarrhoea52
- off label use51
- death48
- dyspnoea48
- product dose omission issue48
- asthenia38
- rash36
- decreased appetite34
- pneumonia33
- vomiting33
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 6 |
| 2011 | 5 |
| 2012 | 15 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 10 |
| 2017 | 19 |
| 2018 | 35 |
| 2019 | 41 |
| 2020 | 49 |
| 2021 | 28 |
| 2022 | 104 |
| 2023 | 123 |
| 2024 | 131 |
| 2025 | 157 |
| 2026 | 119 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,298 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product dose omission issueSignal | 48 | 4.0 | 3.0 | 106 |
| decreased appetiteSignal | 34 | 3.6 | 2.6 | 61 |
| fatigueSignal | 91 | 2.9 | 2.4 | 112 |
| pneumoniaSignal | 33 | 2.5 | 1.8 | 28 |
| astheniaSignal | 38 | 2.5 | 1.8 | 32 |
| nauseaSignal | 76 | 2.3 | 1.9 | 60 |
| headacheSignal | 58 | 2.3 | 1.8 | 41 |
| painSignal | 53 | 2.1 | 1.6 | 31 |
| dyspnoeaSignal | 48 | 2.1 | 1.6 | 26 |
| rashSignal | 36 | 2.0 | 1.5 | 18 |
| diarrhoea | 52 | 2.0 | 1.5 | 25 |
| vomiting | 33 | 1.7 | 1.2 | 9 |
| off label use | 51 | 1.4 | 1.1 | 6 |
| death | 48 | 1.4 | 1.0 | 4 |
| drug ineffective | 65 | 1.2 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.